Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer

Fig. 5

BEZ235 alone or combined with trastuzumab induced cell cycle arrest at G1 phase. ab Flow cytometric analysis showed that the percentage of cells accumulated in G1 phase significantly increased after treatment with trastuzumab alone (54.3 and 49.1 %, respectively), BEZ235 alone (61.3 and 56.5 %, respectively), or BEZ235 combined with trastuzumab (68.5 and 72.2 %, respectively), compared to the control (47.5 and 43.3 %, respectively). c The expression of CDK4 and cyclin D1 was further downregulated by BEZ235 combined with trastuzumab compared to either one inhibitor used individually. The data are expressed as the Mean ± S.D of three independent experiments. *P <0.05 by one-way ANOVA or unpaired two-tailed t-test. Cropped blots were used because the same experimental conditions were used for running all the gels

Back to article page